AnaptysBio Ends Eczema Drug Development After Trial Failure; Q32 Bio Shares Plunge 69%, $ADCT Down 22%, Candel Up 70%

AnaptysBio has announced the termination of its experimental eczema treatment after the drug failed to meet both primary and secondary endpoints in a mid-stage trial. This decision has resulted in a nearly 40% decline in the company's stock price. Concurrently, Q32 Bio has also faced significant setbacks, with its shares dropping approximately 69% following disappointing results from a study of its immune drug. In contrast, Candel has emerged as a leader among biotech gainers, experiencing a nearly 70% increase in stock value due to positive clinical data related to prostate cancer. Other companies such as $CLRB, $ANAB, and $SPRB have also reported declines in their stock prices, reflecting a challenging environment for biotech firms amid recent clinical readouts.